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Anna Djos1, Tommy Martinsson1, Per Kogner3 and Helena Carén1,2*Abstract
Background: Hypermethylation of promotor CpG islands is a common mechanism that inactivates tumor
suppressor genes in cancer. Genes belonging to the RASSF gene family have frequently been reported as
epigenetically silenced by promotor methylation in human cancers. Two members of this gene family, RASSF1A and
RASSF5A have been reported as methylated in neuroblastoma. Data from our previously performed genome-wide
DNA methylation array analysis indicated that other members of the RASSF gene family are targeted by DNA
methylation in neuroblastoma.
Results: In the current study, we found that several of the RASSF family genes (RASSF2, RASSF4, RASSF5, RASSF6,
RASSF7, and RASSF10) to various degrees were methylated in neuroblastoma cell lines and primary tumors. In
addition, several of the RASSF family genes showed low or absent mRNA expression in neuroblastoma cell lines.
RASSF5 and RASSF6 were to various degrees methylated in a large portion of neuroblastoma tumors and RASSF7 was
heavily methylated in most tumors. Further, CpG methylation sites in the CpG islands of some RASSF family members
could be used to significantly discriminate between biological subgroups of neuroblastoma tumors. For example,
RASSF5 methylation highly correlated to MYCN amplification and INRG stage M. Furthermore, high methylation of
RASSF6 was correlated to unfavorable outcome, 1p deletion and MYCN amplification in our tumor material.
In conclusion: This study shows that several genes belonging to the RASSF gene family are methylated in
neuroblastoma. The genes RASSF5, RASSF6 and RASSF7 stand out as the most promising candidate genes for further
investigations in neuroblastoma.Introduction
Neuroblastoma (NB) is the most commonly occurring
solid extra-cranial tumor in children accounting for 6%
of cancer incidence and 9% of cancer deaths in children
[1]. It is a highly clinically and biologically heteroge-
neous cancer of the postganglionic sympathetic nervous
system with tumors developing from immature or dedif-
ferentiated neural crest cells [1,2]. Most tumors originate
in the adrenal medulla or in paraspinal sympathetic gan-
glia. Common genetic alterations in NB tumors are* Correspondence: helena.caren@gu.se
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reproduction in any medium, provided the orMYCN amplification, 17q gain, 1p deletion and loss of
11q [2,3]. The list of genes epigenetically silenced in can-
cer is growing and the inactivated genes represent all
cellular pathways. Several genes have been reported as
silenced by methylation in NB and one example is the
Ras-associated family member RASSF1A, located at
chromosome 3p [4]. CpG island methylation of
RASSF1A has been reported as a frequent event in NB
tumors and cell lines [4] and loss of heterozygozity
(LOH) at 3p, i.e. the loci containing the RASSF1A gene,
has been reported in primary NB tumors [5]. RASSF1A
is also epigenetically silenced by promoter methylation
in many other human tumors [6]. The Ras proto-
oncogenes belong to a super-family of GTPases that par-
ticipate in a range of cellular processes such as cell
growth, adhesion, migration, differentiation and apop-
tosis [7], with defects in Ras signaling pathway resultingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient data
Tumor id Outcome INRG age at diagnosis age at follow up 1p-del MNA 11q-del 17q-gain
10E6 NED M <18 m >60 m pos pos neg pos
10E7 DOD M >18 m <60 m neg neg neg pos
10R2 DOD M <18 m <60 m pos pos neg pos
10R4 NED MS <18 m >60 m neg neg neg neg
10R8 DOD L >18 m <60 m neg neg pos neg
11E1 NED M >18 m >60 m neg neg pos pos
11E8 NED L <18 m >60 m neg neg neg neg
11R9 DOD M >18 m <60 m neg neg pos pos
12E5 NED MS <18 m >60 m neg neg neg neg
12R1 NED M <18 m >60 m pos neg neg pos
12R6 DOD M >18 m <60 m pos pos neg neg
12R9 NED M >18 m >60 m neg pos neg neg
13R0 DOD M >18 m <60 m neg pos pos pos?
13R1 DOD L >18 m <60 m neg pos pos pos
15R8 NED L <18 m >60 m pos neg pos pos
16E2 NED L <18 m >60 m neg neg neg neg
16E9 DOD M >18 m <60 m neg pos neg pos?
16R4 NED L >18 m >60 m neg pos neg pos
17E2 NED L >18 m >60 m neg neg neg neg
17E4 DOD M >18 m <60 m neg pos pos pos
18E2 NED L >18 m >60 m pos neg neg pos
18E4 DOD M <18 m <60 m neg pos pos pos
18E5 NED L >18 m >60 m neg neg neg neg
18E7 NED L >18 m >60 m neg neg neg pos
18E8 NED L <18 m >60 m neg neg neg neg
19R1 NED L >18 m >60 m neg neg neg neg
19R6 DOD L <18 m <60 m neg pos pos pos
20R8 NED L >18 m >60 m neg pos pos pos
23R2 NED L >18 m >60 m neg pos
23R4 NED L <18 m >60 m neg neg neg neg
25R6 DOD M >18 m <60 m neg pos pos pos
25R7 NED L <18 m >60 m neg neg neg neg
26R0 NED M >18 m >60 m pos neg pos pos
26R1 NED L <18 m >60 m neg neg neg neg
27R7 NED L <18 m >60 m neg neg neg neg
28R2 NED <18 m >60 m neg pos pos pos
30R0 NED M >18 m >60 m pos neg neg neg
32R2 NED M >18 m >60 m pos neg pos pos
34R0 DOD M >18 m <60 m neg neg neg pos
34R5 NED L <18 m <60 m neg neg neg neg
35R5 NED L <18 m <60 m neg neg neg neg
35R7 DOD M <18 m <60 m pos neg neg neg
36R1 DOD M >18 m <60 m pos neg neg pos
36R2 NED M >18 m <60 m pos neg neg pos
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Table 1 Patient data (Continued)
36R3 DOD MS <18 m <60 m neg neg neg pos
37R5 NED L <18 m <60 m neg neg neg neg
37R6 NED L <18 m <60 m neg neg neg neg
38R6 NED L >18 m <60 m neg neg pos neg
39R1 NED M >18 m <60 m neg pos pos pos
3E2 DOD M >18 m <60 m pos neg neg pos
43R2 DOD M <18 m <60 m neg neg neg pos
43R3 NED M >18 m <60 m neg pos pos pos
4E1 DOD M >18 m <60 m pos neg neg pos
5E1 NED L <18 m >60 m neg neg neg neg
6E9 DOD L >18 m <60 m pos neg pos pos
8E4 NED L <18 m >60 m neg neg neg neg
8E7 NED L >18 m >60 m neg neg neg neg
9E5 DOD M >18 m <60 m neg pos pos pos
9R9 DOD M >18 m <60 m pos neg pos pos
NED, no evidence of disease; DOD, dead of disease; L, localized; M, metastatic; m, months.
1p-del, 1p-deletion; MNA, MYCN amplification; 11q-del, 11q-deletion; neg, negative; pos, positive.
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their diverse functions via interaction with RASS effec-
tors which have conserved Ras interacting domains. One
of many such Ras interacting domains is the RA-domain,
and the RA-domain is a common feature of the genes in
the Ras-association domain family (RASSF). This family
has ten members; RASSF1-10, which are divided into two
groups, the classical members RASSF1-6 and the N-
terminal members RASSF7-10 [8]. The classical RASSF
family members have been reported to be involved in
many biological processes such as microtubule stability,
cell cycle control and apoptosis and are generally consid-
ered as tumor suppressors [8]. Based on our previous
data using IIumina 27K methylation arrays [9] we noted
that several of the RASSF genes were methylated in NB.
Eight of the RASSF genes were included on the IIumina
27K methylation arrays (RASSF1A, RASSF2, RASSF3,
RASSF4, RASSF5, RASSF6, RASSF7 and RASSF8). The
following seven RASSF genes were chosen for further
methylation analysis; RASSF2, RASSF4, RASSF5, RASSF6,
RASSF7, RASSF8 and RASSF10). The two CpG sites in
RASSF3 were unmethylated in all NB tumors and this
gene was therefore not investigated further. RASSF8 how-
ever, we wanted to include in the verification analysis
with BSP to see if surrounding CpG sites also were
unmethylated since this gene has been reported as
methylated in Childhood Leukemia cell lines [10].
RASSF1A was not analyzed further as this gene is well
known to be deregulated in NB due to DNA methylation.
Recent published data have shown that RASSF10 is
methylated in other cancers which led us to include this
gene in our analyses. In addition to the RASSF1A gene,DNA methylation was found in six out of seven analyzed
RASSF genes (RASSF2, 4, 5–7 and 10). Several of the
RASSF genes had reduced mRNA expression levels in NB
cell lines and the methylation status of some of the
RASSF genes was able to significantly discriminate be-
tween biological subgroups of NB tumors.
Material and methods
Cell lines and tumor material
A panel of nine NB cell lines; Kelly, NB69, SK-N-SH, SH-
SY-5Y, SK-N-AS, SK-N-BE(2), SK-N-DZ, SK-N-FI and
IMR-32 were used for analysis of DNA methylation sta-
tus. All nine NB cell lines were subjected to epigenetic
drug treatment and expression analysis with end-point
RT-PCR or qRT-PCR. In addition, we have previously
generated cDNA microarray data for SK-N-AS, SK-N-BE
(2), SK-N-DZ and IMR-32 [9]. Data from Illumina
Human Methylation27K DNA analysis BeadChips from
fifty-nine primary NB tumors (Table 1) were also used,
together with four NB cell lines, SK-N-AS, SK-N-BE(2),
SK-N-DZ and IMR-32, one adrenal sample, unmethy-
lated and methylated controls (EpiTect control DNA,
Qiagen, Hilden, Germany) [9]. Control for the genomic
content and the authenticy of all cell lines have been per-
formed and genomic profiles of the cell lines generated
[11]. Furthermore, short tandem repeat fingerprinting/
genotyping of all the cell lines used were performed to
verify the identity of cell lines, as described earlier [11].
Analysis of DNA methylation
1 μg of genomic DNA was bisulfite modified using the
EpiTect kit (Qiagen) according to the manufacturer’s
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genes was investigated using bisulfite sequencing,
methylation-specific PCR (MSP) or combined bisulfite
restriction analysis (COBRA).
Methylation-specific PCR (MSP) and bisulfite sequencing
PCR amplifications were performed according to Carén
et al. [9]. Primers were designed with the Bisearch soft-
ware [12] and are listed in Table 2. One fully methylated
control sample, one unmethylated control sample and
one 50/50 mixture of methylated and unmethylated con-
trol (EpiTect) were used to optimize the reaction condi-
tions and to ensure that the bisulfite modified DNATable 2 Primers used in this study
Gene Method Primer sequence
RASSF2A MSP F: 5′-GTTCGTCGTCGTTTTTTAGGCG-3′
R: 5′-AAAAACCAACGACCCCCGCG-3′
RASSF2A MSP F: 5′-AGTTTGTTGTTGTTTTTTAGGTGG-3
R: 5′-AAAAAACCAACAACCCCCACA-3′
RASSF4 COBRA F: 5′-AGGATAYGATATATGTAGTGGTTTT
R: 5′-ATTATAACCCCTAAATTACTTAACA
RASSF5A* BSP F: 5′-TTAGGAAAGAGGAATATTTTAT-3′
R: 5′-TAAACCTTCAACCCTACCTCTTTC-
RASSF5C** BSP F: 5′-GGGGTTTAGAGTTAGGGGTTTA-3′
R: 5′-TATAACTTTATCCCTTTACTA-3′
RASSF6 COBRA F: 5′-GTATAGGGAGTGGTTTAGGTTTTTT
R: 5′-ATCCCCATTTTTTACCTATTATTCAC
RASSF7 BSP F: 5′-GAGAAAAGTTAGGTTTTAGA-3′
R: 5′-CTCAACAACCTTCTAATATAA-3′
RASSF8 BSP F: 5′-TTTTATAATGTAGYGTTGGYGTTTTA
R: 5′-CRAAACTCRACRAAACTAAACRAA
RASSF10 BSP F: 5′-TTGTTTTTGTTGTTTTYGTYGTTTTAG
R: 5′-CRATTAAACTTAACCAATTTACRAA
RASSF2A qRT-PCR F: 5′-AAGGGGTGGAGAGTGATATGAAG
R: 5′-AGGGACGTTTGGTGGCTGTAGT-3′
RASSF4 qRT-PCR F: 5′-GGACTGCGCGATGACTGGAC-3′
R: 5′-CCGACTTCTGAATGGACTTGCTGT-
RASSF5 End-point RT-PCR F: 5′-CCTGGGCATGAAACTGAGTGAAGA
R: 5′-tgatggcatctaggggcaggtaga-3′
RASSF6 End-point RT-PCR F: 5′-ATGGAGAGACTGAAGATGGC-3′
R: 5′-CAGGGTGTTGCTGTGATAAG-3′
RASSF7 End-point RT-PCR F: 5′-CAGCAGAGCGAGCCTTGCAGGCT
R: 5′-CTGAGTGCCAGGAGGGCCCCTGTC
RASSF10 qRT-PCR F: 5′-CCATGACCCAGGAGAAACAG-3′
R: 5′-TGCTGGCGAATTGTGTGGTC-3′
*cg17558126, **cg02589695.
MSP, Methylation specific PCR; BSP, Bisulfite sequencing PCR; COBRA, Combined bis
qRT-PCR, Quantitative real time PCR; AT, Annealing temperature; TD, Touch down.samples were equally amplified despite their methylation
status. PCR products were visualized on a 2% agarose gel
with GelRed (Biotinum, Hayward, CA). The methylation
status of RASSF2A was determined using MSP and the
methylation status of RASSF5, RASSF7, RASSF8 and
RASSF10 were analyzed with bisulfite sequencing [9].
Combined bisulfite restriction analysis (COBRA)
The methylation status of RASSF4 and RASSF6 was
determined using COBRA [16]. Bisulfite modified DNA
was amplified as described above (primers in Table 2).
For RASSF4, 2 μl of PCR product was incubated with
2U BstUI enzyme (CGCG) and 1xNEBuffer4 (NewProduct (bp) AT °C Primer design
109 62 [13]
′ 109 60 [13]
TGGATT-3′ 270 TD 65-55 [14]
AAAATACCAAA-3′
434 TD 60-50 [12]
3′
345 TD 60-50 [12]
GATAT-3′ 353 TD 67-57 [10]
ACTATA-3′
592 TD 62-52 [12]
GTTT-3′ 374 TD 67-57 [10]
AAACT-3′
TAGATT-3′ 634 TD 67-57 [10]
AAACCTTA-3′
AG-3′ 194 60 [15]
126 56 [15]
3′
-3′ 188 56 Manual
203 56 [15]











RASSF1 cg00777121 CGI 0.69 0.13-0.95
cg06063729 CGI 0.02 0-0.05
cg06821120 CGI 0.12 0.02-0.64
cg06980053 CGI 0.20 0.06-0.59
cg08047457 CGI 0.75 0.05-0.99
cg11035216 CGI 0.02 0-0.03
cg15043975 CGI 0.06 0.04-0.11
cg21554552 CGI 0.61 0.04-0.96
cg26357744 CGI 0.01 0-0.04
RASSF2 cg16884569 CGI 0.01 0-0.03
cg19614321 CGI shore 0.06 0.01-0.27
RASSF3 cg07915282 CGI 0.02 0-0.07
cg12157010 CGI 0.01 0-0.02
RASSF4 cg13603099 CGI shore 0.01 0-0.02
cg17324128 CGI 0.10 0.04-0.24
RASSF5 cg01860753 CGI 0.18 0.04-0.38
cg02589695 CGI 0.23 0.06-0.51
cg08617916 CGI 0.01 0-0.02
cg10167296 CGI 0.04 0.02-0.1
cg17558126 CGI 0.13 0.03-0.43
cg19452316 CGI 0.04 0-0.08
cg22857604 CGI 0.04 0-0.1
cg23520347 CGI 0.05 0.01-0.09
cg24450312 CGI 0.09 0.02-0.16
RASSF6 cg03996822 CGI shore 0.39 0-0.94
cg08647446 CGI 0.12 0.05-0.54
RASSF7 cg14896003 CGI shore 0.96 0.89-1.0
RASSF8 cg07469792 CGI 0.01 0-0.03
cg22946876 CGI 0.00 0-0.03
ILMNID, Illumina ID; CGI, CpG island.
ahttp://www.illumina.com/Documents/products/technotes/technote_cpg_loci_
identification.pdf.
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RASSF6, 2 μl of PCR product was incubated with 1U of
FastDigest TaqI (TCGA) and 1X FastDigest Green Buffer
(Fermentas, Germany) for 15 minutes at 65°C. Digestion
patterns were visualized on a 2% agarose gel with
GelRed (Biotinum).
Epigenetic drug treatments and expression analysis
Changes in gene expression following treatment with the
demethylating agent, 5-Aza-2′-deoxycytidine (5-Aza-dC;
Sigma-Aldrich co, St Louis, MO) or/and the histone dea-
cetylase inhibitor trichostatin A (TSA; Sigma-Aldrich)
were analyzed with either end-point RT-PCR or qRT-
PCR using Sybergreen (Applied Biosystems, Foster City,
CA). RNA extraction and cDNA synthesis were done as
previously described [9]. End-point RT-PCR was used for
RASSF5, RASSF6 and RASSF7. PCR reactions were dena-
tured at 96°C for 10 minutes, followed by 35 cycles of 96°
C for 30 seconds, annealing temperature (Table 2) for 30
seconds and 72°C for 30 seconds ending with a 7 minute
extension step at 72°C. PCR products were taken at dif-
ferent time points (cycle 25, 30 and 35) to ensure the de-
tection of the amplification product in the exponential
phase. The housekeeping gene GUSB was included as an
endogenous control. The end-point RT-PCR products
were run on a 2% agarose gel and fragments were visua-
lized with UV-light using GelRed (Biotinum). Quantita-
tion of end-point RT-PCR was performed with ImageJ
1.45 software (NIH, Bethesta, MO) and normalization
was done using GUSB. For the genes RASSF2A, RASSF4
and RASSF10, expression analysis was performed with
qRT-PCR using Sybergreen (Applied Biosystems) and the
SDS software was used to extract Ct-values. Quantifica-
tion was performed with the standard curve method [17].
GUSB was used for normalization.
Statistical analysis
The methylation beta-values from the CpG sites where
methylation of the RASSF genes were detected were
extracted from the 27K methylation arrays [9] and the
difference in beta-values (methylation frequency) be-
tween different biological subgroups of NB were com-
pared with Student’s two-sided t-test. The tests included
INRG stage, 5-year overall survival (5-OS), MYCN amp-
lification status, 1p deletion, and 11q deletion. Correc-
tion for multiple testing was done with Bonferroni
correction. The IIumina ID’s of the CpG sites on the
27K methylation array are listed in Table 3.
Results
Methylation analysis with methylation array, bisulfite
sequencing, MSP and COBRA
Bisulfite sequencing, MSP and COBRA assays were per-
formed in order to verify that the methylated CpG sitespresent on the 27K methylation array were indeed
methylated and to explore if surrounding CpG sites had
the same methylation status. Six of the seven RASSF
genes were found to have methylated CpG islands in at
least one NB cell line. Our 27K methylation array data
showed dense RASSF1A methylation of NB primary
tumors and cell lines which were expected since
RASSF1A is well-known to be deregulated by DNA
methylation in NB.
The RASSF2A MSP results confirmed the 27K methy-
lation array data in that the cell line SK-N-AS showed
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was generally not found in primary NB tumors; only a
few cases with low grade methylation were detected.
The RASSF4 gene region that was analyzed with
COBRA showed very low level of methylation in three
cell lines; SK-N-AS, IMR-32 and Kelly. The 27K methy-
lation array showed that RASSF4 are generally not
methylated in primary NB tumors even though some
tumors had low level of methylation (methylation fre-
quency below 25%).
Many of the primary NB tumors showed various levels
of RASSF5 methylation of at least one of the CpG sites
present on the array, whereas some tumors were
unmethylated at all sites present on the array (Table 3).
SK-N-AS, IMR-32, SK-N-DZ and SK-N-BE(2) all showed
partial methylation of RASSF5 in at least one CpG site
on the 27K methylation array. Two bisulfite sequencing
assays were designed in order to confirm the RASSF5






Figure 1 RASSF5 methylation and correlation to INRG stage and MYC
RASSF5A CpG island: top sequence NB69 and bottom sequence Kelly. CpG
C/T in the sequence indicate partial methylation. (B) High methylation of R
amplification. P-values are indicated in the left upper corner in each graph
the 75th percentile and 25th respectively; whiskers show highest and loweCpG rich region upstream of the promoter where the
longest RASSF5 transcript (RASSF5A) is initiated. The
other targeted a CpG rich region in the promoter where
the medium-sized RASSF5 transcript (RASSF5C) is
initiated. Bisulfite sequencing showed that the CpG site
cg17558126, located just upstream of RASSF5A was
methylated in 7/9 NB cell lines and the site cg02589695,
located in RASSF5C was methylated in 6/9 NB cell lines.
For example the NB cell line NB69 was fully methylated
whereas Kelly was partially methylated at the CpG sites
in the RASSF5A fragment (Figure 1A). Bisulfite sequen-
cing of RASSF5 thus confirmed the 27K methylation
array results for both CpG sites. In NB primary tumors,
the methylation frequency (methylation beta-values) of
two of the CpG sites on the 27K methylation array were
significantly higher in INRG stage M compared to stage
L (p-values <0.001, Bonferroni corrected <0.02 for all
sites), (Figure 1B). The methylation beta-values were also
for two of the sites significantly higher in MYCN-MYCN amplification
100.0=p
N amplification. (A) Examples of bisulfite sequencing of RASSF5 in the
sites are underlined and C in the sequence indicates methylation and
ASSF5 is significantly correlated to INRG stage M and MYCN
. Box plot explanation; upper and lower hinges of the box represent
st values. Open circles represent outliers and asterisks show extremes.
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roni corrected p-values <0.02), (Figure 1B).
The 27K methylation array showed partial RASSF6
methylation of at least one of the two CpG sites present
on the array in all NB cell lines. The analyzed CpG island
region of RASSF6 was shown to be methylated in six out
of nine (67%) cell lines according to our COBRA results
(Figure 2A). The COBRA results thus confirmed partial
methylation of RASSF6 in IMR-32 and SK-N-BE(2) as
well as the lower level of methylation in SK-N-AS. The
methylation beta-values were significantly higher in
patients with an unfavorable 5-year overall survival (Bon-
ferroni corrected p-value <0.03), (Figure 2B). A higher
methylation was also detected in 1p-deleted and MYCN-
amplified tumors, with the most significant site located
in the CpG island shore (Bonferroni corrected p-values
of <5x10-7 and p< 2x10-4, respectively, Figure 2C).
The CpG site present on the 27K methylation array,
located in the gene body of RASSF7 was fully methylated
in all four NB cell lines. Bisulfite sequencing of a frag-
ment surrounding the transcriptional start site of
RASSF7 showed that eight of the nine (89%) NB cell lines
were methylated, although to various levels (Figure 3).





Figure 2 RASSF6 methylation and correlation to outcome, 1p deletion
of RASSF6. PCR products are cleaved with TaqI. Samples from left to right: K
IMR-32, methylated control (MQ), unmethylated control (UQ) and a 50% m
(MQ/UQ). (B) High methylation of RASSF6 is correlated to an unfavorable o
deletion and MYCN amplification.were methylated also around the RASSF7 transcription
start site.
RASSF8 was unmethylated in all NB cell lines accord-
ing to the 27K methylation array and bisulfite sequen-
cing confirmed the array results. RASSF8 was also
unmethylated in the NB tumor material.
RASSF10 was unmethylated in eight of the nine
(89%) cell lines whereas NB69 was partially methylated
at all CpG sites. The methylation results are summar-
ized in Figure 4A and the methylation frequencies of
each CpG site on the 27K methylation array are listed
in Table 3.
Expression analysis and up-regulation after 5-aza-dC and
TSA treatment
RASSF2A mRNA expression in NB cell lines was very
low overall, with no difference in expression between
methylated and unmethylated cell lines (Figure 4B).
Quantitative real-time PCR showed that RASSF2A
expression was up-regulated in 4/9 NB cell lines after
5-Aza-dC/TSA treatment (Table 4).
RASSF4 expression was present in all NB cell lines
with a lower expression in Kelly, SH-SY-5Y, SK-N-BE(2)
and IMR-32 (Figure 4B). The lower expression in Kelly,MYCN amplificationdeletion
E1p 4
and MYCN amplification. (A) Combined bisulfite restriction analysis
elly, NB69, SK-N-SH, SH-SY-5Y, SK-N-AS, SK-N-BE(2), SK-N-DZ, SK-N-FI,
ixture of methylated and unmethylated control
utcome. (C) High methylation of RASSF6 is highly correlated to 1p
NB69
IMR 32
Figure 3 Bisulfite sequencing of RASSF7. Top sequence NB69 and bottom sequence IMR-32. Cytosines/thymines in the CpG dinucleotide are
underlined. C in the sequence indicates methylation, C/T indicates partial methylation and T indicates unmethylated CpG sites.
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methylation according to either COBRA or 27K methy-
lation array results. Further, the three cell lines (SK-N-
AS, IMR-32 and SK-N-BE(2)), that showed low level ofFigure 4 Summary of RASSF gene expression and methylation. (A) Su
frequencies for each gene and NB cell line are indicated with a color code
marked with yellow. (B) Summary of RASSF gene expression in NB cell line
with a color code where blue indicate absent expression and yellow highmethylation on the 27K methylation array were
up-regulated following treatment with 5-Aza-dC and
even more up-regulated following a combined treatment
with 5-Aza-dC and TSA. The methylated cell line Kellymmary of RASSF gene methylation in NB cell lines. Methylation
where fully methylated is marked with blue and unmethylated is
s. mRNA expression levels for each gene and NB cell line are marked
expression level.
Table 4 Up-regulation of gene expression following treatment with 5-Aza-dC or 5-Aza-dC/TSA
Rassf2A* Rassf4* Rassf5** Rassf6** Rassf7** Rassf10*
Kelly AZA UD
AZA/TSA " UD " "
NB69 AZA " UD
AZA/TSA " " UD
SK-N-SH AZA UD
AZA/TSA UD
SH-SY-5Y AZA " UD "
AZA/TSA " " UD
SK-N-AS AZA " " UD
AZA/TSA " UD
SK-N-BE(2) AZA " " UD
AZA/TSA " " UD "




IMR-32 AZA " " UD
AZA/TSA " " " UD
Arrows indicate a more than 2 fold up-regulation of gene expression following treatment.
UD, undetermined - gene transcripts not detected in the PCR amplification.
*qRT-PCR, **End-point RT-PCR.
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bined treatment with 5-Aza-dC and TSA (Table 4).
RASSF5 expression varied between the cell lines and
RASSF5 mRNAs was up-regulated after epigenetic treat-
ment in 6/9 of the NB cell lines (see Figure 4B, Figure 5
and Table 4). The highest level of up-regulation was seen
in the cell lines IMR-32 and SH-SY-5Y.SK N SHKelly NB69 SH SY5Y
SK N DZ
SK N BE(2)SK N AS
SK N FI IMR 32 Pos.ctrl NTC
A B C A B C A B C
A B C A B C A B C A B CA B CA B C
Figure 5 Up-regulation of RASSF5 expression following
treatment with 5-Aza-dC and TSA. RASSF5 end-point RT-PCR
samples from left to right: Kelly A, B, C, NB69 A, B, C, SK-N-SH A, B, C,
SH-SY-5Y A, B, C, SK-N-AS A, B, C, SK-N-BE(2) A, B, C, SK-N-DZ A, B, C,
SK-N-FI A, B, C, IMR-32 A, B, C. Three positive controls (Pos. ctrl) and
one non template control (NTC). A = untreated, B = AZA treated and
C=AZA/TSA treated.RASSF6 was not expressed in seven out of the nine
(78%) NB cell lines and the remaining two had expres-
sion just above the detection limit. No up-regulation was
seen following treatment with either 5-Aza-dC alone or
in conjunction with TSA (Figure 4B and Table 4).
RASSF7 expression was overall very low in the NB cell
lines with exception for SK-N-FI which had moderate
expression (Figure 4B). RASSF7 expression was strongly
up-regulated in the methylated cell line SK-N-BE(2) after
treatment with 5-Aza-dC in conjunction with TSA with
both cDNA microarray and end-point RT-PCR. RASSF7
was up-regulated in 4/9 NB cell lines following at least
one of the treatments (Table 4).
Very low RASSF10 expression was detected in five of
the nine (56%) NB cell lines (Figure 4B). RASSF10 ex-
pression was not up-regulated following epigenetic treat-
ment in most of the NB cell lines (Table 4).Discussion
In this study, we investigated whether the RASSF family
genes are epigenetically silenced in NB. Data from our
previously performed 27K methylation array showed that
members of the RASSF gene family were methylated in
NB cell lines and tumors [9]. The methylation status
observed with the 27K methylation array was verified by
DNA methylation analysis using bisulfite sequencing,
MSP or COBRA, of the corresponding CpG island.
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RASSF7 (eight out of nine cell lines methylated), RASSF5
(six to seven out of nine cell lines methylated depending
on region analyzed) and RASSF6 (six out of nine cell
lines methylated) (Figure 4A). Gene expression analysis
performed on NB cell lines showed in general low to
moderate expression of the RASSF genes (Figure 4B).
RASSF4 had the highest expression in the NB cell lines
whereas the mRNA levels of RASSF6, RASSF7 and
RASSF10 were either below detection levels or very low
in most NB cell lines. Also, the mRNA levels of
RASSF2A and RASSF5 were low in general. In order to
see if RASSF gene expression could be restored, NB cell
lines were treated with 5-Aza-dC/or TSA. Gene expres-
sion of most of the RASSF genes (RASSF2A, RASSF4,
RASSF5, RASSF7 and RASSF10) was up-regulated fol-
lowing epigenetic treatment, suggesting these genes may
be epigenetically regulated. The concentration of each
epigenetic drug and the treatment time will mostTable 5 Information of the RASSF genes studied in relation to
Symbol Chr Product Methylated in cancer
RASSF1A 3p21 Ras association domain
family member 1
NB tumors and cell lines [
as various human cancers
in [6]
RASSF2 20p13 Ras association domain
family member 2
Colorectal cancer [13], gas
nasopharyngeal carcinoma
lung and NSCLC tumors [2
cancer [23], pancreatic can
RASSF4 10q11 Ras association domain
family member 4
Kidney-, breast- and lung
breast- and lung primary t
RASSF5 1q32 Ras association domain
family member 5
NB cell lines [26]; [27], lung
colorectal-, and kidney tum
and in primary NSCLC tum
tumor [29], CCRCC [30], ga
colon cancer [13], squamo
of head and neck [31], hep
carcinoma [32]
RASSF6 4q13 Ras association domain
family member 6
Childhood leukemia [10]
RASSF7 11p15 Ras association domain
family (N-terminal)
member 7
RASSF8 12p12 Ras association domain
family (N-terminal)
member 8
Childhood leukemia cell li
RASSF10 11p15 Ras association domain
family (N-terminal)
member 10
Childhood leukemia [10], t
cancer [40], primary gliobl
and astrocytomas [41], ma
melanoma [42]
Chr, chromosome; TSG, tumor suppressor gene; KO, knock out; NSCLS, non-small ce
heterozygosity.certainly affect the results of up-regulation. The chosen
conditions of drugs and treatment times were based
upon optimization conditions where re-expression of a
panel of known methylated genes occurred [9]. More
gene-specific optimizations of the epigenetic drug treat-
ment conditions may be necessary in order to explore
the re-activation potential fully. Also, up-regulation of a
gene may be the result of their up-stream regulators
being affected by treatment and it is also possible that
other epigenetic mechanisms than DNA methylation are
responsible for the up-regulation. Genes belonging to
the RASSF family are generally considered as TSGs and
many of the members have been reported as silenced by
promoter methylation in human cancers, (Table 5).
RASSF1A is a TSG involved in a range of cellular pro-
cesses that are essential for normal cell growth control.
Rassf1a is one of the most commonly inactivated pro-
teins in cancer and inactivation by promotor hyper-




TSG involved in regulation of cell proliferation.
Promotes apoptosis and cell cycle arrest, involved
in migration and maintenance of genomic stability
(reviewed in [6]). KO of RASSF1A in mice enhances





Function as a TSG, reduces colony formation,
promotes apoptosis and cell cycle arrest [25];
[15]; [21]; [22]; [23]
cancer cell lines,
umors [14]
Have growth inhibitory properties and promotes







Also called NORE1 and forms heterodimers with
RASSF1A [33]. Associate with microtubules and act
growth inhibitory by a process involving p53.
Promotes apoptosis when overexpressed or in the
presence of activated Ras [34]. Neuroblastoma
tumors, especially non MYCN-amplified, show
suppressed NORE1A expression [27]
Putative TSG in childhood leukemia [10]. Promotes
apoptosis [35]. Downregulated at both mRNA and
protein level in gastric cancer. Gastric cancer
patients with RASSF6-negative tumors had worse
outcome and higher recurrence rate than patients
with RASSF6-positive tumors [36]
Centrosome associated protein necessary for
spindle formation and completion of mitosis in the
neural tube in Xenopus [8]. Required for completion
of mitosis in human cells and KO results in mitotic
arrest [37]
nes [10] TSG candidate in lung cancer [38]. KO enhances
anchorage independent growth in soft agar and




Suggested as a regulator of mitosis. Over-expression
decrease colony formation in soft agar [41]
ll lung cancer; CCRCC, clear cell renal cell carcinoma; LOH, loss of
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idity of our 27K methylation array data, we detected
dense RASSF1A methylation of NB primary tumors and
cell lines, which is in agreement with published data.
RASSF2A mRNA expression was in the current study
generally low in NB cell lines and up-regulation of
RASSF2A was seen following a combined treatment with
5-Aza-dC and TSA (4/9 NB cell lines) even though
methylation at the RASSF2A CpG island was not com-
monly observed.
RASSF4 mRNA expression was detected in all NB cell
lines and 5-Aza-dC and TSA treatment resulted in up-
regulation of RASSF4 mRNA levels in 5/9 NB cell lines.
The strongest up-regulation was detected in the cell line
IMR-32 which also showed the highest methylation level.
RASSF5, also called NORE1 (Novel Ras Effector 1), is
localized at 1q32.1 and has a 60% similarity to RASSF1A,
the most commonly described methylated gene in cancer
so far. The RASSF5 gene encodes at least three different
isoforms due to different promoter usage and alternative
splicing. Two of the RASSF5 isoforms, RASSF5A and
RASSF5C are broadly expressed in most normal tissues.
RASSF5A is the longest isoform transcribed from the
most 5′-promoter and the isoform RASSF5B is produced
by alternative splicing. The shorter isoform RASSF5C is
transcribed from a more downstream promoter. Pro-
moter methylation of RASSF5A has been reported to not
occur in primary NB tumors and there are some conflict-
ing data concerning methylation of NB cell lines, where
NB cell lines have been described as low methylated or
unmethylated in different studies [26,27]. Interestingly
RASSF5 was recently shown to be demethylated and up-
regulated in the NB cell line SK-N-BE during ATRA-
induced differentiation [43], suggesting that RASSF5
could be aberrantly methylated in undifferentiated NB
tumors cells but demethylated and re-expressed through
differentiation. According to our 27K methylation array
data, two CpG sites were methylated in NB primary
tumors and cell lines. The methylated CpG sites were
located in different RASSF5 promotor CpG islands. The
27K methylation array site cg17558126 was located in
the most 5′-promoter where transcription of RASSF5A
starts and cg02589695 were located in a downstream
promoter were the RASSF5C transcript starts. Bisulfite
sequencing of the two regions revealed that both CpG
sites present on the 27K methylation array were indeed
methylated in most NB cell lines (Figure 4A). The methy-
lation status of the CpG sites surrounding cg17558126
(RASSF5A) was highly variable throughout the CpG is-
land, but most sites showed partial methylation, whereas
the CpG sites surrounding cg02589695 (RASSF5C) were
unmethylated in all NB cell lines. The variable methyla-
tion of CpG sites in this island might explain why there
are conflicting published data regarding the methylationstatus of RASSF5A in NB cell lines. Gene expression of
RASSF5A have also been described as low in NB cell
lines, with the highest expression in SK-N-SH and ab-
sent expression in IMR-32 [26], which is in agreement
with our data (Figure 4A and 4B). RASSF5 mRNA ex-
pression was in this study up-regulated for several NB cell
lines. For example, the methylated cell line SH-SY-5Y was
up-regulated after 5-Aza-dC treatment and even more up-
regulated following a combined treatment with both 5-
Aza-dC and TSA (Table 4). Two of the analyzed RASSF5
CpG sites on the 27K methylation array were signifi-
cantly more methylated in INRG stage M tumors com-
pared to L tumors (Figure 1B). Also, RASSF5A
methylation was highly correlated to MYCN amplification
(Figure 1B). RASSF5A mRNA expression have also been
reported as frequently down-regulated in NB and pheo-
chromocytoma primary tumors and lower RASSF5A ex-
pression was seen in NB tumors without MYCN-
amplification compared to MYCN-amplified tumors [27].
The methylation beta-value for two of the RASSF5 sites
was significantly higher in MYCN-amplified tumors com-
pared to non-amplified tumors which contradicts an earl-
ier report that showed lower expression of this gene in
non-MYCN-amplified tumors [27].
RASSF6, located at chromosome region 4q13.3 has re-
cently been suggested as a TSG candidate in childhood
leukemia and was found to be silenced by heavy methy-
lation across the whole CpG island in leukemia cell lines
[10]. In the current study, RASSF6 promoter methylation
was found in 6/9 NB cell lines and RASSF6 expression
was absent or just above detection level in the panel of
NB cell lines (Figure 4A and 4B). High methylation of
RASSF6 was significantly correlated to unfavorable out-
come (5-OS), 1p deletion and MYCN amplification in
our patient cohort (Figure 2B and 2C). Recently, RASSF6
was shown to be down-regulated at both mRNA and
protein level in gastric cancer tumors and loss of
RASSF6 expression correlated with poor survival and
increased tumor recurrence rate [36]. Functional studies
have indicated that RASSF6 is involved in promoting
apoptosis [35].
RASSF7, also known as HRC1 (HRAS1 cluster 1), is
located at chromosome region 11p15.5 and lacks the
conserved SARAH domain present in RASSF1-6. To our
knowledge, there are yet no reports of epigenetic silen-
cing of RASSF7 in cancer but important functions have
been reported (Table 5). In this study, bisulfite sequen-
cing showed methylation of the RASSF7 promotor CpG
sites in 8/9 NB cell lines (Figure 4A). All four NB cell
lines present on the 27K methylation array were heavily
methylated (84-96%) at the analyzed CpG site. Interest-
ingly, the mRNA expression of RASSF7 was very low or
absent in most NB cell lines (Figure 4B). According to
our cDNA microarray analysis the methylated NB cell
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genetic treatment, which was verified with end-point RT-
PCR (Table 4).
RASSF10, located at 11p15.2, has recently been
reported as methylated and silenced in childhood
leukemia [10], thyroid cancer [40] and in astrocytic gli-
oma [41]. In this study the RASSF10 mRNA expression
was absent or just above the detection level in NB cell
lines but low methylation was found in only 1/9 NB cell
lines (Figure 4A and B).
Collectively, the RASSF family members have been
demonstrated to have several tumor suppressive proper-
ties (Table 5). Although RASSF proteins lack catalytic
activity, they are suggested to be non-enzymatic adap-
tors that are involved in growth and tumor suppression.
The molecular mechanisms behind their growth sup-
pressing properties are not yet elucidated but a number
of reports show association with microtubules or centro-
meres indicating that the RASSF genes are important in
microtubule dynamics and mitosis. In addition, the
RASSF family genes participate in regulation of apoptosis
and epigenetic silencing of RASSF genes may contribute
to cancer by preventing RAS induced-apoptosis. In a
normal cell, there is an important balance between sig-
naling pathways that promote survival and those who
promote apoptosis. If RASSF genes are silenced, the pro-
apoptotic effects of RAS signaling may be lost which
may favor the balance towards the pro-survival PI3 kin-
ase pathway. Future studies regarding the exact function
of the RASSF family genes and their interacting partners
are essential to elucidate the role that epigenetic silen-
cing of RASSF genes might play in NB and cancer in
general.
Several genes from various cellular pathways have been
reported as epigenetically silenced by DNA methylation
in NB. For example, Caspase-8 (CASP8) located at 2q33
was one of the first genes to be reported as methylated in
NB [44]. Aberrantly methylated genes could in the future
be used in clinical patient stratification as biomarkers or
as therapeutic targets. Our group and many others have
shown that DNA methylation of single genes or a
selected group of genes, are able to predict patient out-
come, for a review see Decock et al., [45]. Epigenetic in-
activation of RASSF1A has been reported as associated
with high risk disease, age >1 year and poor survival for
NB patients [46]. Further, RASSF1A hypermethylation in
serum from patients with NB has been reported as a reli-
able prognostic predictor [47].
In summary, in addition to RASSF1A which is already
known as frequently methylated in NB, this study high-
lights the RASSF gene family members RASSF5, RASSF6
and RASSF7 as promising candidates for further analysis
in NB. These three genes are targeted by DNA methyla-
tion in NB primary tumors and cell lines and show lowlevels of mRNA expression in NB cell lines. Also, CpG
site specific DNA methylation of RASSF5 and RASSF6
was able to significantly discriminate between different
subgroups of NB.
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